Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH-mutant grade 4 astrocytoma: a comparison integrating the clinical, pathological, and survival features between primary and secondary patients.

Journal of neurosurgery - 1 Jan 2024

Liu Yanwei, Gao Dezhi, Chen Huiyuan, Zhang Jing, Yao Kun, Wu Chenxing, Li Shouwei, Yan Wei, Qiu Xiaoguang

Abstract excerpt

OBJECTIVE: IDH-mutant grade 4 astrocytomas (AIDHmut/G4) are divided into primary de novo (pAIDHmut/G4) and secondary with a history of prior lower-grade gliomas (LGGs; sAIDHmut/G4). The mutational spectrum and DNA methylation patterns are homogeneous within de novo pAIDHmut/G4 and evolved sAIDHmut/G4, but the two groups have different diagnoses, management, and outcomes. This study sought to systematically...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Astrocytoma
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methylation

Share to Glioblastoma

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Progression-Free Survival

Source

Identifiers

PMID: 37410628
DOI: 10.3171/2023.5.JNS222658

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH-mutant grade 4 astrocytoma: a comparison integrating the clinical, pathological, and survival features between primary and secondary patients.PMID 37410628Read ↗

Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors.Semantic proximity Read ↗

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.Semantic proximity Read ↗

An Analysis for IDH-Mutant Grade 4 Astrocytoma Based on WHO CNS 5: Implication of Clinical Practice.Semantic proximity Read ↗

cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas.Semantic proximity Read ↗

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.Semantic proximity Read ↗

Canonical amplifications and CDKN2A/B loss refine IDH1/2-mutant astrocytoma prognosisSemantic proximity Read ↗

IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.Semantic proximity Read ↗

Dissecting the prognostic signature of patients with astrocytoma isocitrate dehydrogenase-mutant grade 4: a large multicenter, retrospective study.Semantic proximity Read ↗

IDH mutant high-grade gliomasSemantic proximity Read ↗

Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.Semantic proximity Read ↗

Management for Different Glioma Subtypes: Are All Low-Grade Gliomas Created Equal?Semantic proximity Read ↗

Molecular characteristics of incidental lower-grade glioma for treatment decision-making.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.